Introduction
1
The voltage-gated sodium channel Nav1.2, encoded by SCN2A, plays a critical 2
role in the initiation and propagation of action potentials in excitatory neurons, thereby 3
shaping cortical network excitability and information processing [Catterall, 1992; 4
Catterall et al., 2005]. Nav1.2 is abundantly expressed in the axons of cortical and 5
hippocampal excitatory neurons [Liao et al., 2010; Ogiwara et al., 2018; Yamagata et 6
al., 2023], as well as in dopaminergic neurons in the substantia nigra pars compacta and 7
ventral tegmental area (VTA) [Yang et al., 2019]. In addition, Nav1.2 is present in 8
specific populations of inhibitory neurons, including medium spiny neurons (MSNs) in 9
the striatum [Miyazaki et al., 2014] and GABAergic interneurons in the neocortex [Li et 10
al., 2014; Yamagata et al., 2017]. 11
Pathogenic mutations in SCN2A have been implicated in a broad spectrum of 12
neurodevelopmental and neuropsychiatric disorders, including epilepsy, autism 13
spectrum disorder (ASD), intellectual disability (ID), and schizophrenia [Sugawara et 14
al, 2001; Kamiya et al, 2004; Ogiwara et al, 2009; Buxbaum et al, 2012; Rauch et al, 15
2012; de Ligt et al, 2012; Tavassoli et al, 2014; Fromer et al, 2014; Hoischen et al, 16
2014; Li et al, 2016; Johnson et al, 2016; Carroll et al, 2016; Balakrishna et al, 2020]. 17
Consistent with these clinical findings, rodent models with Scn2a haploinsufficiency 18
exhibit epileptic phenotypes, cognitive impairments, and behavioral abnormalities 19
reminiscent of SCN2A-associated disorders in humans [Ogiwara et al., 2018; Middleton 20
et al., 2018; Tatsukawa et al., 2019; Suzuki et al., 2024]. Our previous studies using 21
genetic models of SCN2A- and STXBP1-related epilepsies demonstrated that reduced 22
excitatory transmission from cortical pyramidal neurons onto striatal parvalbumin-23
expressing (PV+) fast-spiking interneurons (FSIs) is sufficient to trigger epilepsy 24
.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
The copyright holder for this preprintthis version posted April 16, 2026. ; https://doi.org/10.64898/2026.04.15.718826doi: bioRxiv preprint
5
[Ogiwara et al., 2018; Miyamoto et al., 2019]. Consistently, pharmacological inhibition 1
of cortico-striatal excitatory inputs onto FSIs using Ca²⁺-permeable AMPA receptor 2
antagonist induces generalized seizures in both rodents and non-human primates [Gittis 3
et al., 2011; Aupy et al., 2024]. More recently, we further demonstrated that selective 4
suppression of PV+ FSIs in the anteromedial shell of the NAc is sufficient to elicit 5
convulsive seizures, underscoring the critical role of striatal microcircuits in seizure 6
generation [Suzuki et al., 2026]. These findings highlight the importance of cortico-7
striatal circuits and PV⁺ FSIs in regulating network excitability. Accumulating evidence 8
also suggests that SCN2A dysfunction contributes to behavioral abnormalities relevant 9
to psychiatric disorders. For example, mice with Scn2a deficiency in brain regions 10
implicated in schizophrenia and ASD, such as the medial prefrontal cortex (mPFC) and 11
the VTA, display alterations in prepulse inhibition (PPI) of the acoustic startle response 12
[Suzuki et al., 2024]. PPI is widely recognized as an endophenotype of schizophrenia 13
[Braff et al., 2001; Geyer et al., 2006; Powell et al., 2009; Takahashi et al., 2011; Mena 14
et al., 2016]. In addition, mice lacking Scn2a in the mPFC exhibit increased sociability, 15
decreased locomotor activity, and enhanced anxiety-like behavior, whereas mice lacking 16
Scn2a in the VTA show minimal behavioral abnormalities apart from altered vertical 17
activity. These observations suggest that Scn2a dysfunction in distinct brain regions 18
may differentially contribute to schizophrenia- and ASD-related phenotypes. In contrast, 19
other group reported that deletion of Scn2a in VTA dopaminergic neurons reduces 20
neuronal firing and dopamine release, leading to hyperactivity, impaired sociability, and 21
reduced anxiety-like behavior [Li et al., 2025]. Similar abnormalities are observed in 22
systemic Scn2a heterozygous knockout mice (Scn2a+/-) and are alleviated by acute 23
levodopa administration, indicating dopamine system hypofunction [Li et al., 2025]. 24
.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
The copyright holder for this preprintthis version posted April 16, 2026. ; https://doi.org/10.64898/2026.04.15.718826doi: bioRxiv preprint
6
Based on these findings, dysfunction of SCN2A-dependent neural circuits, 1
including cortico-striatal and mesolimbic dopamine pathways, has been proposed to 2
contribute to the pathophysiology of ASD and schizophrenia. However, the circuit 3
mechanisms through which Scn2a dysfunction leads to social behavioral abnormalities 4
remain incompletely understood. In the present study, we sought to elucidate the neural 5
circuit mechanisms underlying ASD-related social behavioral deficits associated with 6
SCN2A dysfunction. In particular, we focused on the NAc, a key node in cortico-limbic 7
circuits that integrates excitatory inputs from the cerebral cortex, hippocampus, and 8
amygdala and regulates emotional and motivational behaviors. Using conditional 9
genetic and chemogenetic approaches, we show that Scn2a haploinsufficiency in dorsal 10
telencephalic excitatory neurons and selective inhibition of NAc PV⁺ FSIs reduce 11
sociability. Furthermore, these behavioral abnormalities occur without detectable 12
reductions in dopamine release in the NAc, suggesting that impaired activity of 13
excitatory neurons or FSIs in cortico-striatal circuits may contribute to social behavioral 14
deficits independently of mesolimbic dopamine hypofunction. 15
16
.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
The copyright holder for this preprintthis version posted April 16, 2026. ; https://doi.org/10.64898/2026.04.15.718826doi: bioRxiv preprint
7
Methods
1
Animals 2
All mice were maintained under a 12 h light/dark cycle with ad libitum access to food 3
and water. Scn2a floxed mice [Ogiwara et al., 2018], in which exon 2 is flanked by loxP 4
sites, and Empty spiracles homolog 1 (Emx1)-Cre knock-in mice [Iwasato et al., 2000; 5
Iwasato et al., 2004] were maintained on a C57BL/6J background. To generate Scn2a 6
conditional knockout mice, homozygous Scn2a floxed (Scn2afl/fl) mice were crossed 7
with Emx1-Cre knock-in mice. Parvalbumin (PV)-Cre transgenic mice [Tanahira et al., 8
2009] were maintained on a C57BL/6J background. Scn2a heterozygous knock-out 9
(Scn2a+/-) mice were described previously [Planells-Cases et al., 2000] and were 10
maintained on a C57BL/6J background. 11
12
AA Vs 13
The plasmid construct for double floxed Gi-coupled hM4D DREADD fused with 14
mCherry under the control of EF1a promoter (pAA V-EF1a-DIO-hM4D(Gi)-mCherry) 15
was a gift from Dr. Bryan Roth (Addgene plasmid 50461). Packaging of the plasmid 16
vector into AA Vs, as well as purification and quantification of the viruses, were 17
performed at the Division of Genetic Therapeutics, Jichi Medical University, and at the 18
section for Viral Vector Development, National Institute of Physiological Sciences. 19
20
Stereotaxic surgery 21
PV-Cre transgenic mice (>8 weeks of age, both sexes) were anesthetized with isoflurane 22
(1.0–2.5%) and placed in a stereotaxic apparatus (Stoelting). Bilateral injections of 23
AA V5-EF1α-DIO-hM4D(Gi)-mCherry (7.5 × 1012 viral genomes/ml; 250 nl per site) or 24
.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
The copyright holder for this preprintthis version posted April 16, 2026. ; https://doi.org/10.64898/2026.04.15.718826doi: bioRxiv preprint
15
phosphate-buffered saline (PBS; 250 nl per site) into the NAc were performed using a 1
microinjector (Nanoliter 2020 Injector; World Precision Instruments) fitted with a 2
pulled glass capillary at a flow rate of 100 nl/min. Stereotaxic coordinates were 3
determined based on a mouse brain atlas [Paxinos et al., 2001]: NAc (anteroposterior, 4
mediolateral, and dorsoventral, in mm): +1.60, ±1.00, -5.00 and -4.50; and +0.80, 5
±1.00, -5.20 and -4.50. 6
7
Measurements of dopamine release 8
Extracellular dopamine levels in the NAc of male mice aged 8–15 months were 9
quantified utilizing an in vivo microdialysis system. Under anesthesia induced by a 10
combination of medetomidine (0.3 mg/kg), midazolam (4 mg/kg), and butorphanol (5 11
mg/kg), a guide cannula (AG-6; EICOM) was implanted into the NAc shell. The 12
coordinates for implantation, based on the mouse brain atlas [Paxinos et al., 2001], were 13
as follows (in mm): anteroposterior +1.30, mediolateral +0.70, dorsoventral -4.20. The 14
cannula was affixed to the skull using stainless steel screws and dental acrylic cement. 15
Three to four days post-surgery, a dialysis probe equipped with a 1 mm-length 16
membrane (FX-I-6-01, EICOM) was inserted into the guide cannula. This probe was 17
perfused with artificial cerebrospinal fluid, composed of 147.2 mM NaCl, 4.0 mM KCl, 18
and 2.3 mM CaCl2, at a flow rate of 0.8 μl/min using a microsyringe injector (ESP-64, 19
EICOM). Dialysate samples were collected and injected every 30 minutes using an auto 20
injector (EAS-20S, EICOM). The samples were subsequently separated using an SC-21
50DS column (EICOM) to facilitate dopamine measurement via high-performance 22
liquid chromatography (HPLC) with an electrochemical detection system (HTEC-500, 23
EICOM), where the working electrode was maintained at +700 mV (vs. Ag/AgCl) at a 24
.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
The copyright holder for this preprintthis version posted April 16, 2026. ; https://doi.org/10.64898/2026.04.15.718826doi: bioRxiv preprint
16
temperature of 25 °C. The mobile phase consisted of 83 % 0.1 M citrate/0.1 M sodium 1
acetate buffer (pH 3.9) and 17 % methanol, containing 140 mg/l sodium 1-2
octanesulfonate and 5 mg/l EDTA-2Na, delivered at a flow rate of 0.23 ml/min. 3
Protocol was controlled and data analysis was performed using Power Chrom software 4
(ADI instruments Japan). 5
The animal was acclimated for over two hours in the experimental arena, which 6
measured 30 × 30 × 35 cm, until the baseline stabilized. Following the two-hour 7
measurement period (four samples), the animals were administered methamphetamine 8
(1.0 mg/kg, i.p.), and samples were obtained for more than two hours. 9
10
Three‐chamber social approach test 11
The three-chamber apparatus consisted of a rectangular clear Plexiglas box (43 × 63 12
cm) divided into three equal-sized chambers (21 × 43 cm) by transparent Plexiglas 13
partitions with small openings that allowed mice to freely move between chambers. A 14
cylindrical wire cage was placed in each corner of the two side chambers to enclose an 15
unfamiliar 11–12-week-old C57BL/6J male mouse (stranger). Test male mice (3–5 16
months of age) were first habituated to the apparatus for 10 min, with an empty wire 17
cage placed in each of the side chambers. For the sociability test, a wire cage containing 18
a stranger mouse was placed in one side chamber, and the subject mouse was initially 19
placed in the center chamber and allowed to freely explore the entire apparatus for a 10 20
min. The location of the stranger mouse (left or right chamber) was alternated between 21
trials. Behavior was recorded using a video camera mounted above the apparatus. The 22
total time spent in proximity to each cage (empty or containing the stranger mouse) was 23
quantified manually in a blinded manner. 24
.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
The copyright holder for this preprintthis version posted April 16, 2026. ; https://doi.org/10.64898/2026.04.15.718826doi: bioRxiv preprint
17
1
Startle response and prepulse inhibition (PPI) test 2
The startle response and PPI test was conducted as previously described [Nakao et al., 3
2015; Suzuki et al., 2024]. Male mice (6–8 months of age) were placed in a Plexiglas 4
cylinder with a continuous 70 dB white noise background and allowed to habituate for 5 5
min. An acoustic startle stimulus (40 ms; 110- or 120-dB) was presented either alone or 6
preceded by a prepulse stimulus (20 ms; 74- or 78-dB) during the PPI trials. Each test 7
block consisted of two startle alone trials (110- and 120-dB) and four prepulse–startle 8
trials (74-dB prepulse + 110- or 120-dB startle; 78-dB prepulse + startle 110- or 120-dB 9
startle). Each mouse underwent ten blocks. The inter-trial interval varied randomly with 10
an average of 15 s (range: 10–20 s). Startle responses and PPI were recorded 11
automatically. 12
13
Open field test 14
Male mice (3–4 months of age) were placed in a corner of a square open-field apparatus 15
(45 × 45 × 20 cm) illuminated at 100 lx and allowed to freely explore for 120 min. The 16
total distance traveled (cm) and the time spent in the center area (20 × 20 cm) were 17
automatically recorded using manufacturer’s software (Smart3.0, PanLab). 18
19
Statistical analyses 20
Data were analyzed using Student's t-test for two-group comparisons or one-way or 21
two-way analysis of variance (ANOV A), followed by Tukey’s post hoc test for 22
parametric data (KyPlot; KyensLab Inc.), as appropriate. Data are presented as the mean 23
± standard error of the mean (s.e.m.) or as box-and-whisker plots. In the box-and-24
.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
The copyright holder for this preprintthis version posted April 16, 2026. ; https://doi.org/10.64898/2026.04.15.718826doi: bioRxiv preprint
18
whisker plots, the boxes indicate the median (thick line), the 25th and 75th percentiles, 1
and the whiskers represent the minimum and maximum values. Statistical significance 2
was defined as P < 0.05. 3
4
.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
The copyright holder for this preprintthis version posted April 16, 2026. ; https://doi.org/10.64898/2026.04.15.718826doi: bioRxiv preprint
19
Acknowledgments 1
The authors thank Drs. Tamamaki and Tanahira (Kumamoto University) for generously 2
providing the PV-Cre-TG driver line. We also thank the members of the Department of 3
Neurophysiology and Brain Science, the Endowed Department of Cognitive Function 4
and Pathology, the Department of Neurodevelopmental Disorder Genetics, and the staff 5
of the animal facility at Nagoya City University (NCU) for their support. We are 6
grateful to the Research Equipment Sharing Center at NCU for technical assistance. 7
8
Author Contributions 9
TS and KaY contributed to the study conception and design. Material preparation, data 10
collection, and analysis were performed by TS, ST, YY, HM, KK, WN, KoY , TK, YH, 11
TY , SI, HN, HH, KaY . The first draft of the manuscript was written by TS and K aY . All 12
authors have reviewed and approved the final manuscript. 13
14
Funding 15
This work was supported by grants from NCU; JSPS KAKENHI (Grant Numbers 16
22K07620 to TS, 23K27490 to KaY and 25K10820 to TS); and the Grant-in-Aid for 17
Outstanding Research Group Support Program at NCU (Grant Number 2401101). This 18
study also utilized research equipment shared under the MEXT Project for Promoting 19
Public Utilization of Advanced Research Infrastructure (Program for Supporting 20
Construction of Core Facilities; Grant Number JPMXS0441500024). 21
22
Data Availability 23
The datasets generated during and/or analyzed during the current study are available 24
.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
The copyright holder for this preprintthis version posted April 16, 2026. ; https://doi.org/10.64898/2026.04.15.718826doi: bioRxiv preprint
20
from the corresponding author on reasonable request. 1
2
Declarations 3
Ethics Approval 4
All animal breeding and experimental procedures were approved by the Institutional 5
Animal Care and Use Committee of NCU (approval No. 19-032, approved 20 Dec 6
2022; approval No. 23-024, approved 21 Apr 2023). All procedures were conducted in 7
accordance with the ARRIVE guidelines and the institutional guidelines and regulations 8
of NCU. 9
10
Consent to Participate 11
Not applicable. 12
13
Consent for Publication 14
Not applicable. 15
16
Competing Interests 17
The authors declare no competing interests. 18
19
.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
The copyright holder for this preprintthis version posted April 16, 2026. ; https://doi.org/10.64898/2026.04.15.718826doi: bioRxiv preprint
21
References
1
1. Aupy J, Ribot B, Guehl D, Nguyen TH, Burbaud P (2023) Selective striatal fast-2
spiking interneuron inhibition induces cortical seizure. J Neurosci Res 102 3
(1):e25270. doi:10.1002/jnr.25270 4
2. Balakrishna T, Curtis D (2020) Assessment of Potential Clinical Role for Exome 5
Sequencing in Schizophrenia. Schizophr Bull 46 (2):328-335. 6
doi:10.1093/schbul/sbz057 7
3. Braff DL, Geyer MA, Swerdlow NR (2001) Human studies of prepulse inhibition of 8
startle: normal subjects, patient groups, and pharmacological studies. 9
Psychopharmacology (Berl) 156 (2-3):234-258. doi:10.1007/s002130100810 10
4. Buxbaum JD, Daly MJ, Devlin B, Lehner T, Roeder K, State MW, Autism 11
Sequencing C (2012) The autism sequencing consortium: large-scale, high-12
throughput sequencing in autism spectrum disorders. Neuron 76 (6):1052-1056. 13
doi:10.1016/j.neuron.2012.12.008 14
5. Carroll LS, Woolf R, Ibrahim Y , Williams HJ, Dwyer S, Walters J, Kirov G, 15
O'Donovan MC, Owen MJ (2016) Mutation screening of SCN2A in schizophrenia 16
and identification of a novel loss-of-function mutation. Psychiatr Genet 26 (2):60-17
65. doi:10.1097/YPG.0000000000000110 18
6. Castro DC, Bruchas MR (2019) A Motivational and Neuropeptidergic Hub: 19
Anatomical and Functional Diversity within the Nucleus Accumbens Shell. Neuron 20
102 (3):529-552. doi:10.1016/j.neuron.2019.03.003 21
7. Catterall WA (1992) Cellular and molecular biology of voltage-gated sodium 22
channels. Physiol Rev 72 (4 Suppl):S15-48. 23
doi:10.1152/physrev.1992.72.suppl_4.S15 24
.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
The copyright holder for this preprintthis version posted April 16, 2026. ; https://doi.org/10.64898/2026.04.15.718826doi: bioRxiv preprint
22
8. Catterall WA, Goldin AL, Waxman SG (2005) International Union of Pharmacology. 1
XLVII. Nomenclature and structure-function relationships of voltage-gated sodium 2
channels. Pharmacol Rev 57 (4):397-409. doi:10.1124/pr.57.4.4 3
9. de Ligt J, Willemsen MH, van Bon BW, Kleefstra T, Yntema HG, Kroes T, Vulto-4
van Silfhout AT, Koolen DA, de Vries P, Gilissen C, del Rosario M, Hoischen A, 5
Scheffer H, de Vries BB, Brunner HG, Veltman JA, Vissers LE (2012) Diagnostic 6
exome sequencing in persons with severe intellectual disability. N Engl J Med 367 7
(20):1921-1929. doi:10.1056/NEJMoa1206524 8
10. Fromer M, Pocklington AJ, Kavanagh DH, Williams HJ, Dwyer S, Gormley P, 9
Georgieva L, Rees E, Palta P, Ruderfer DM, Carrera N, Humphreys I, Johnson JS, 10
Roussos P, Barker DD, Banks E, Milanova V , Grant SG, Hannon E, Rose SA, 11
Chambert K, Mahajan M, Scolnick EM, Moran JL, Kirov G, Palotie A, McCarroll 12
SA, Holmans P, Sklar P, Owen MJ, Purcell SM, O'Donovan MC (2014) De novo 13
mutations in schizophrenia implicate synaptic networks. Nature 506 (7487):179-14
184. doi:10.1038/nature12929 15
11. Geyer MA (2006) The family of sensorimotor gating disorders: comorbidities or 16
diagnostic overlaps? Neurotox Res 10 (3-4):211-220. doi:10.1007/BF03033358 17
12. Gittis AH, Leventhal DK, Fensterheim BA, Pettibone JR, Berke JD, Kreitzer AC 18
(2011) Selective inhibition of striatal fast-spiking interneurons causes dyskinesias. J 19
Neurosci 31 (44):15727-15731. doi:10.1523/JNEUROSCI.3875-11.2011 20
13. Hoischen A, Krumm N, Eichler EE (2014) Prioritization of neurodevelopmental 21
disease genes by discovery of new mutations. Nat Neurosci 17 (6):764-772. 22
doi:10.1038/nn.3703 23
14. Iwasato T, Datwani A, Wolf AM, Nishiyama H, Taguchi Y , Tonegawa S, Knopfel T, 24
.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
The copyright holder for this preprintthis version posted April 16, 2026. ; https://doi.org/10.64898/2026.04.15.718826doi: bioRxiv preprint
23
Erzurumlu RS, Itohara S (2000) Cortex-restricted disruption of NMDAR1 impairs 1
neuronal patterns in the barrel cortex. Nature 406 (6797):726-731. 2
doi:10.1038/35021059 3
15. Iwasato T, Nomura R, Ando R, Ikeda T, Tanaka M, Itohara S (2004) Dorsal 4
telencephalon-specific expression of Cre recombinase in PAC transgenic mice. 5
Genesis 38 (3):130-138. doi:10.1002/gene.20009 6
16. Johnson MR, Shkura K, Langley SR, Delahaye-Duriez A, Srivastava P, Hill WD, 7
Rackham OJ, Davies G, Harris SE, Moreno-Moral A, Rotival M, Speed D, 8
Petrovski S, Katz A, Hayward C, Porteous DJ, Smith BH, Padmanabhan S, Hocking 9
LJ, Starr JM, Liewald DC, Visconti A, Falchi M, Bottolo L, Rossetti T, Danis B, 10
Mazzuferi M, Foerch P, Grote A, Helmstaedter C, Becker AJ, Kaminski RM, Deary 11
IJ, Petretto E (2016) Systems genetics identifies a convergent gene network for 12
cognition and neurodevelopmental disease. Nat Neurosci 19 (2):223-232. 13
doi:10.1038/nn.4205 14
17. Kamiya K, Kaneda M, Sugawara T, Mazaki E, Okamura N, Montal M, Makita N, 15
Tanaka M, Fukushima K, Fujiwara T, Inoue Y , Yamakawa K (2004) A nonsense 16
mutation of the sodium channel gene SCN2A in a patient with intractable epilepsy 17
and mental decline. J Neurosci 24 (11):2690-2698. doi:10.1523/JNEUROSCI.3089-18
03.2004 19
18. Li J, Cai T, Jiang Y , Chen H, He X, Chen C, Li X, Shao Q, Ran X, Li Z, Xia K, Liu 20
C, Sun ZS, Wu J (2016) Genes with de novo mutations are shared by four 21
neuropsychiatric disorders discovered from NPdenovo database. Mol Psychiatry 21 22
(2):290-297. doi:10.1038/mp.2015.40 23
19. Li L, Huang Q, Hu J, Jin M, Zhuo Y , Ke W, He Q, Xiao Y , Zhang X, Wang W, 24
.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
The copyright holder for this preprintthis version posted April 16, 2026. ; https://doi.org/10.64898/2026.04.15.718826doi: bioRxiv preprint
24
Cheng TL, Tai Y , Guo F, Yu J, Yulong L, He J, Li B, Shu Y (2025) Selective loss of 1
Scn2a in ventral tegmental area dopaminergic neurons leads to dopamine system 2
hypofunction and autistic-like behaviors. Neuron 113 (18):2997-3014 e2998. 3
doi:10.1016/j.neuron.2025.06.003 4
20. Li T, Tian C, Scalmani P, Frassoni C, Mantegazza M, Wang Y , Yang M, Wu S, Shu 5
Y (2014) Action potential initiation in neocortical inhibitory interneurons. PLoS 6
Biol 12 (9):e1001944. doi:10.1371/journal.pbio.1001944 7
21. Liao Y , Deprez L, Maljevic S, Pitsch J, Claes L, Hristova D, Jordanova A, Ala-8
Mello S, Bellan-Koch A, Blazevic D, Schubert S, Thomas EA, Petrou S, Becker AJ, 9
De Jonghe P, Lerche H (2010) Molecular correlates of age-dependent seizures in an 10
inherited neonatal-infantile epilepsy. Brain 133 (Pt 5):1403-1414. 11
doi:10.1093/brain/awq057 12
22. Marinescu AM, Labouesse MA (2024) The nucleus accumbens shell: a neural hub at 13
the interface of homeostatic and hedonic feeding. Front Neurosci 18:1437210. 14
doi:10.3389/fnins.2024.1437210 15
23. Mena A, Ruiz-Salas JC, Puentes A, Dorado I, Ruiz-Veguilla M, De la Casa LG 16
(2016) Reduced Prepulse Inhibition as a Biomarker of Schizophrenia. Front Behav 17
Neurosci 10:202. doi:10.3389/fnbeh.2016.00202 18
24. Middleton SJ, Kneller EM, Chen S, Ogiwara I, Montal M, Yamakawa K, McHugh 19
TJ (2018) Altered hippocampal replay is associated with memory impairment in 20
mice heterozygous for the Scn2a gene. Nat Neurosci 21 (7):996-1003. 21
doi:10.1038/s41593-018-0163-8 22
25. Miyamoto H, Tatsukawa T, Shimohata A, Yamagata T, Suzuki T, Amano K, Mazaki 23
E, Raveau M, Ogiwara I, Oba-Asaka A, Hensch TK, Itohara S, Sakimura K, 24
.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
The copyright holder for this preprintthis version posted April 16, 2026. ; https://doi.org/10.64898/2026.04.15.718826doi: bioRxiv preprint
25
Kobayashi K, Kobayashi K, Yamakawa K (2019) Impaired cortico-striatal 1
excitatory transmission triggers epilepsy. Nat Commun 10 (1):1917. 2
doi:10.1038/s41467-019-09954-9 3
26. Miyazaki H, Oyama F, Inoue R, Aosaki T, Abe T, Kiyonari H, Kino Y , Kurosawa M, 4
Shimizu J, Ogiwara I, Yamakawa K, Koshimizu Y , Fujiyama F, Kaneko T, Shimizu 5
H, Nagatomo K, Yamada K, Shimogori T, Hattori N, Miura M, Nukina N (2014) 6
Singular localization of sodium channel beta4 subunit in unmyelinated fibres and its 7
role in the striatum. Nat Commun 5:5525. doi:10.1038/ncomms6525 8
27. Nakao A, Miki T, Shoji H, Nishi M, Takeshima H, Miyakawa T, Mori Y (2015) 9
Comprehensive behavioral analysis of voltage-gated calcium channel beta-10
anchoring and -regulatory protein knockout mice. Front Behav Neurosci 9:141. 11
doi:10.3389/fnbeh.2015.00141 12
28. Ogiwara I, Ito K, Sawaishi Y , Osaka H, Mazaki E, Inoue I, Montal M, Hashikawa T, 13
Shike T, Fujiwara T, Inoue Y , Kaneda M, Yamakawa K (2009) De novo mutations of 14
voltage-gated sodium channel alphaII gene SCN2A in intractable epilepsies. 15
Neurology 73 (13):1046-1053. doi:10.1212/WNL.0b013e3181b9cebc 16
29. Ogiwara I, Miyamoto H, Tatsukawa T, Yamagata T, Nakayama T, Atapour N, Miura 17
E, Mazaki E, Ernst SJ, Cao D, Ohtani H, Itohara S, Yanagawa Y , Montal M, Yuzaki 18
M, Inoue Y , Hensch TK, Noebels JL, Yamakawa K (2018) Nav1.2 haplodeficiency 19
in excitatory neurons causes absence-like seizures in mice. Commun Biol 1:96. 20
doi:10.1038/s42003-018-0099-2 21
30. Paxinos G, Franklin KBJ (2001) The mouse brain in stereotaxic coordinates. 2nd 22
edn. Academic Press, San Diego ; London 23
31. Planells-Cases R, Caprini M, Zhang J, Rockenstein EM, Rivera RR, Murre C, 24
.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
The copyright holder for this preprintthis version posted April 16, 2026. ; https://doi.org/10.64898/2026.04.15.718826doi: bioRxiv preprint
26
Masliah E, Montal M (2000) Neuronal death and perinatal lethality in voltage-gated 1
sodium channel alpha(II)-deficient mice. Biophys J 78 (6):2878-2891. 2
doi:10.1016/S0006-3495(00)76829-9 3
32. Powell SB, Zhou X, Geyer MA (2009) Prepulse inhibition and genetic mouse 4
models of schizophrenia. Behav Brain Res 204 (2):282-294. 5
doi:10.1016/j.bbr.2009.04.021 6
33. Qi J, Zhang S, Wang HL, Barker DJ, Miranda-Barrientos J, Morales M (2016) VTA 7
glutamatergic inputs to nucleus accumbens drive aversion by acting on GABAergic 8
interneurons. Nat Neurosci 19 (5):725-733. doi:10.1038/nn.4281 9
34. Rauch A, Wieczorek D, Graf E, Wieland T, Endele S, Schwarzmayr T, Albrecht B, 10
Bartholdi D, Beygo J, Di Donato N, Dufke A, Cremer K, Hempel M, Horn D, Hoyer 11
J, Joset P, Ropke A, Moog U, Riess A, Thiel CT, Tzschach A, Wiesener A, 12
Wohlleber E, Zweier C, Ekici AB, Zink AM, Rump A, Meisinger C, Grallert H, 13
Sticht H, Schenck A, Engels H, Rappold G, Schrock E, Wieacker P, Riess O, 14
Meitinger T, Reis A, Strom TM (2012) Range of genetic mutations associated with 15
severe non-syndromic sporadic intellectual disability: an exome sequencing study. 16
Lancet 380 (9854):1674-1682. doi:10.1016/S0140-6736(12)61480-9 17
35. Scofield MD, Heinsbroek JA, Gipson CD, Kupchik YM, Spencer S, Smith AC, 18
Roberts-Wolfe D, Kalivas PW (2016) The Nucleus Accumbens: Mechanisms of 19
Addiction across Drug Classes Reflect the Importance of Glutamate Homeostasis. 20
Pharmacol Rev 68 (3):816-871. doi:10.1124/pr.116.012484 21
36. Sugawara T, Tsurubuchi Y , Agarwala KL, Ito M, Fukuma G, Mazaki-Miyazaki E, 22
Nagafuji H, Noda M, Imoto K, Wada K, Mitsudome A, Kaneko S, Montal M, 23
Nagata K, Hirose S, Yamakawa K (2001) A missense mutation of the Na+ channel 24
.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
The copyright holder for this preprintthis version posted April 16, 2026. ; https://doi.org/10.64898/2026.04.15.718826doi: bioRxiv preprint
27
alpha II subunit gene Na(v)1.2 in a patient with febrile and afebrile seizures causes 1
channel dysfunction. Proc Natl Acad Sci U S A 98 (11):6384-6389. 2
doi:10.1073/pnas.111065098 3
37. Suzuki T, Hattori S, Mizukami H, Nakajima R, Hibi Y , Kato S, Matsuzaki M, Ikebe 4
R, Miyakawa T, Yamakawa K (2024) Inversed Effects of Nav1.2 Deficiency at 5
Medial Prefrontal Cortex and Ventral Tegmental Area for Prepulse Inhibition in 6
Acoustic Startle Response. Mol Neurobiol 61 (2):622-634. doi:10.1007/s12035-023-7
03610-6 8
38. Suzuki T, Kondo T, Yamagata T, Hibi Y , Mizukami H, Kobayashi K, Yamakawa K 9
(2026) Reduced activity of nucleus accumbens parvalbumin-expressing fast-spiking 10
inhibitory neurons causes convulsive seizures. bioRxiv:2026.2003.2009.710428. 11
doi:10.64898/2026.03.09.710428 12
39. Takahashi H, Hashimoto R, Iwase M, Ishii R, Kamio Y , Takeda M (2011) Prepulse 13
inhibition of startle response: recent advances in human studies of psychiatric 14
disease. Clin Psychopharmacol Neurosci 9 (3):102-110. 15
doi:10.9758/cpn.2011.9.3.102 16
40. Tanahira C, Higo S, Watanabe K, Tomioka R, Ebihara S, Kaneko T, Tamamaki N 17
(2009) Parvalbumin neurons in the forebrain as revealed by parvalbumin-Cre 18
transgenic mice. Neurosci Res 63 (3):213-223. doi:10.1016/j.neures.2008.12.007 19
41. Tatsukawa T, Raveau M, Ogiwara I, Hattori S, Miyamoto H, Mazaki E, Itohara S, 20
Miyakawa T, Montal M, Yamakawa K (2019) Scn2a haploinsufficient mice display 21
a spectrum of phenotypes affecting anxiety, sociability, memory flexibility and 22
ampakine CX516 rescues their hyperactivity. Mol Autism 10:15. 23
doi:10.1186/s13229-019-0265-5 24
.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
The copyright holder for this preprintthis version posted April 16, 2026. ; https://doi.org/10.64898/2026.04.15.718826doi: bioRxiv preprint
28
42. Tavassoli T, Kolevzon A, Wang AT, Curchack-Lichtin J, Halpern D, Schwartz L, 1
Soffes S, Bush L, Grodberg D, Cai G, Buxbaum JD (2014) De novo SCN2A splice 2
site mutation in a boy with Autism spectrum disorder. BMC Med Genet 15:35. 3
doi:10.1186/1471-2350-15-35 4
43. Xu Y , Lin Y , Yu M, Zhou K (2024) The nucleus accumbens in reward and aversion 5
processing: insights and implications. Front Behav Neurosci 18:1420028. 6
doi:10.3389/fnbeh.2024.1420028 7
44. Yamagata T, Ogiwara I, Mazaki E, Yanagawa Y , Yamakawa K (2017) Nav1.2 is 8
expressed in caudal ganglionic eminence-derived disinhibitory interneurons: 9
Mutually exclusive distributions of Nav1.1 and Nav1.2. Biochem Biophys Res 10
Commun 491 (4):1070-1076. doi:10.1016/j.bbrc.2017.08.013 11
45. Yamagata T, Ogiwara I, Tatsukawa T, Suzuki T, Otsuka Y , Imaeda N, Mazaki E, 12
Inoue I, Tokonami N, Hibi Y , Itohara S, Yamakawa K (2023) Scn1a-GFP transgenic 13
mouse revealed Nav1.1 expression in neocortical pyramidal tract projection 14
neurons. Elife 12. doi:10.7554/eLife.87495 15
46. Yang J, Xiao Y , Li L, He Q, Li M, Shu Y (2019) Biophysical Properties of Somatic 16
and Axonal V oltage-Gated Sodium Channels in Midbrain Dopaminergic Neurons. 17
Front Cell Neurosci 13:317. doi:10.3389/fncel.2019.00317 18
19
.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
The copyright holder for this preprintthis version posted April 16, 2026. ; https://doi.org/10.64898/2026.04.15.718826doi: bioRxiv preprint
29
Figure Legends 1
Figure 1. Reduced cortico-accumbal excitatory input and suppression of FSIs in 2
the NAc impair sociability. (A) Schematic of the experimental design. (B) Schematic 3
illustration of neural circuits projecting to the NAc. (C) During the sociability phase of 4
the three-chamber social approach test, Scn2afl/+/Emx1-Cre mice spent less time around 5
the cage containing a stranger mouse, whereas control mice showed a clear preference 6
for the cage containing the stranger mouse over the empty cage. (D, E) In the sociability 7
phase of the three-chamber test, PV-Cre/NAc-hM4Di mice exhibited normal sociability 8
before CNO administration (Pre-CNO; D), but showed reduced sociability after CNO 9
administration (Post-CNO; E). Black dots represent individual mice. The number of 10
mice in each group is indicated in parentheses. 3ch test, three-chamber test; AA V, 11
adeno-associated virus; AMG, amygdala; CNO, clozapine-N-oxide; CTX, neocortex; 12
FSI, fast-spiking interneuron; HIPP, hippocampus; MSN, medium spiny neuron; NAc, 13
nucleus accumbens; OF test, open field test; PBS, phosphate-buffered saline; PPI test, 14
prepulse inhibition test; PV+, parvalbumin-positive. 15
16
Figure 2. Selective Scn2a deficiency in dorsal telencephalic excitatory neurons 17
shows a trend toward reduced PPI. (A) Acoustic startle responses to two sound 18
stimulus intensities (110- and 120-dB) did not differ significantly between 19
Scn2afl/+/Emx1-Cre mice and control Scn2afl/+ mice. (B) In the PPI test, the percentage 20
PPI of the startle response to a 120-dB pulse preceded by 74- or 78-dB prepulses 21
showed a trend toward reduction in Scn2afl/+/Emx1-Cre mice compared with control 22
mice. Black dots represent individual mice, and the number of mice is indicated in 23
parentheses. 24
.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
The copyright holder for this preprintthis version posted April 16, 2026. ; https://doi.org/10.64898/2026.04.15.718826doi: bioRxiv preprint
30
Figure 3. Inactivation of NAc FSIs does not affect exploratory or anxiety-like 1
behavior in the open field test. (A) Total distance traveled in the open field test did not 2
differ between PV-Cre/hM4Di mice and control mice injected with PBS into the NAc, 3
either before (−) and after (+) CNO administration. (B) Time spent in the center zone of 4
the open field area was comparable between PV-Cre/hM4Di mice and control mice 5
injected with PBS into the NAc, both before (−) and after (+) CNO administration. 6
Black dots represent individual mice, and the number of mice in each group is indicated 7
in parentheses. 8
9
Figure 4. Dopamine release in the NAc is comparable between Scn2a mutant and 10
control mice. Dopamine release in the NAc of Scn2afl/+/Emx1-Cre mice (A, B) and 11
Scn2a+/- mice (C, D) was measured under a novel environmental condition (A, C) and 12
following methamphetamine administration (B, D). Data are presented as mean ± s.e.m. 13
(A, C) or as box-and-whisker plots (B, D). Black dots represent individual mice (B, D), 14
and the number of mice in each group is indicated in parentheses (A–D). DA, 15
dopamine. 16
17
Figure 5. Cortico-accumbal circuit models for sociability and PPI in Scn2a mutant 18
mice. Schematic models of neural circuit underlying sociability and prepulse inhibition 19
(PPI) in Scn2a mutant mice. These diagrams are modified and simplified from previous 20
published models [Swerdlow et al., 2001; Miyamoto et al., 2019; Cano et al., 2021; 21
Suzuki et al., 2024; Suzuki et al., 2026], and incorporate interpretations based on the 22
present findings. Hypothetical neural circuit models illustrating the mechanisms 23
underlying reduced PPI in Scn2afl/+/Emx1-Cre mice (A) and PV-Cre/hM4Di mice (B). 24
.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
The copyright holder for this preprintthis version posted April 16, 2026. ; https://doi.org/10.64898/2026.04.15.718826doi: bioRxiv preprint
31
Upward and downward arrows indicate increased and decreased neural transmission, 1
respectively. CN, cochlear nuclei; CTX, neocortex; D1R, dopamine D1 receptor; D2R, 2
dopamine D2 receptor; DA-N, dopaminergic neuron (gray circle) and transmission 3
(gray arrows); FSI, fast-spiking interneuron; GABA, GABAergic neurons (black 4
circles) and transmission (black lines); Glu, glutamatergic neurons (white circles) and 5
transmission (black arrows); Gly, glycinergic neurons (striped circle) and transmission 6
(gray lines); iCS, intratelencephalic cortico-striatal neurons; IN, interneurons; MDT, 7
mediodorsal thalamus; MSN, medium spiny neuron; NAc, nucleus accumbens; Nav1.1, 8
voltage-gated sodium channel α1 subunit; Nav1.2, voltage-gated sodium channel α2 9
subunit; PnC, caudal pontine reticular nucleus; PPI, prepulse inhibition; PPTg, 10
pedunculopontine tegmental nucleus; SMN, spinal motor nerve; VP, ventral pallidum; 11
VTA, ventral tegmental area. 12
.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
The copyright holder for this preprintthis version posted April 16, 2026. ; https://doi.org/10.64898/2026.04.15.718826doi: bioRxiv preprint
Figure 1
A
Birth
320
3ch test
4 5 6 7 8 9 101
PPI test
Scn2a fl/+/Emx1 -Cre
months of age
Dopamine
measurement
Birth
320 4 5 6 7 8 9 101
Scn2a +/–
months of age
Dopamine
measurement
11 12 13 14 15 16
Birth AAV
Injection
months of age
320
OF test 3ch test
4 5 6 7 8 9 101
PPI test
PV-Cre/NAc -hM4D(Gi)
Empty Stranger
0
50
100
150
200
250
Pre-CNO
Time around cage (s)
0
40
80
120
160
Time around cage (s)
Empty Stranger
NAc-hM4D(Gi)
(n=12)
Empty Stranger Empty Stranger
NAc-PBS
(n=14)
Post-CNO
NAc-hM4D(Gi)
(n=12)
NAc-PBS
(n=14)
P=3.72E-06 P=1.78E-05 P=3.65E-03
D E
Three-chamber test
0
50
100
150
200
250
300
350
Empty Stranger Empty Stranger
Scn2afl/+/Emx1-Cre
(n=18)
Scn2afl/+
(n=16)
P=1.38E-03
Time around cage (s)
C Three-chamber testB
CTX, HIPP, AMG, etc.
Nav1.2+
Emx1+
NAc
FSI MSN
PV+
Glu
Glu GABA
.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
The copyright holder for this preprintthis version posted April 16, 2026. ; https://doi.org/10.64898/2026.04.15.718826doi: bioRxiv preprint
Figure 2
0
0.02
0.04
0.06
0.08
0.10
0.12
Startle amplitude
-150
-100
-50
0
50
100
110dB
74dB
Pre-puls inhibition (%)
Scn2a fl/+ (n=16)
Scn2a fl/+/Emx1 -Cre (n=18)
78dB
120dB
74dB 78dBPre-pulse
Startle
Prepulse inhibition of startle response
110dB 120dB
A B
.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
The copyright holder for this preprintthis version posted April 16, 2026. ; https://doi.org/10.64898/2026.04.15.718826doi: bioRxiv preprint
Figure 3
0
20,000
40,000
60,000
80,000
100,000
120,000
140,000
160,000
0
500
1,000
1,500
2,000
2,500
3,000
3,500
Total distance (cm)
Time in center (s)
A B
– + – +
NAc-hM4D(Gi)
(n=12)
NAc-PBS
(n=14)
NAc-hM4D(Gi)
(n=12)
NAc-PBS
(n=14)
CNO – + – +CNO
Open field test
.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
The copyright holder for this preprintthis version posted April 16, 2026. ; https://doi.org/10.64898/2026.04.15.718826doi: bioRxiv preprint
Methamphetamine
administration
0
50
100
150
200
0-30 30-60 60-90 90-120
DA (% basal)
Time (min)
Novel environment
Scn2a(fl/+)/Emx1-Cre (n=6)
Scn2a(fl/+) (n=6)
0
50
100
150
0-30 30-60 60-90 90-120
DA (% basal)
Time (min)
Novel environment
Scn2a(+/-) (n=8)
WT (n=8)
0
5,000
10,000
15,000
20,000
25,000
DA (% basal)
Scn2a +/-
(n=8)
Scn2a +/+
(n=8)
0
1,000
2,000
3,000
4,000DA (% basal)
Methamphetamine
administration
A B
C D
Scn2a +/– (n=8)
Scn2a +/+ (n=8)
Scn2a fl/+/Emx1 -Cre (n=6)
Scn2a fl/+ (n=6)
Figure 4
Scn2afl/+/Emx1-Cre
(n=5)
Scn2a fl/+
(n=6)
Dopamine measurement
Dopamine measurement
.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
The copyright holder for this preprintthis version posted April 16, 2026. ; https://doi.org/10.64898/2026.04.15.718826doi: bioRxiv preprint
Figure 5
Glu GABA increase decreaseDopamine
NAc VTANav1.1+
PV+ FSI
Nav1.2+
D1R+
MSN
GABA
IN
Nav1.2+
DA-N
VP MDT
Nav1.2+
D2R+
MSN
PV+
??
?
CTX
NAc VTANav1.1+
PV+ FSI
Nav1.2+
D1R+
MSN
GABA
IN
Nav1.2+
DA-N
VP MDT
Nav1.2+
D2R+
MSN
Nav1.2+
iCS
PV+
??
?
CTXNav1.2+
iCS
Scn2afl/+/Emx1-Cre PV-Cre/NAc-hM4D(Gi)A B
PPTg
CN
PnC
Gly
SMNstartle response
PPI
?
?
?
?
?
?
PPTg
CN
PnC
SMNstartle response
PPI?
?
?
?
?
?? ?
? ?
? ?
? ?
.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
The copyright holder for this preprintthis version posted April 16, 2026. ; https://doi.org/10.64898/2026.04.15.718826doi: bioRxiv preprint